Search

Carminic acid is a C-glucosylated octaketide anthraquinone and the main constituent of the natural dye carmine (E120), possessing unique coloring, stability, and solubility properties. Despite being used since ancient times, longstanding efforts to elucidate its route of biosynthesis have been unsuccessful. Herein, a novel combination of enzymes derived from a plant (Aloe arborescens, Aa), a bacterium (Streptomyces sp. R1128, St), and an insect (Dactylopius coccus, Dc) that allows for the biosynthesis of the C-glucosylated anthraquinone, dcII, a precursor for carminic acid, is reported. The pathway, which consists of AaOKS, StZhuI, StZhuJ, and DcUGT2, presents an alternative biosynthetic approach for the production of polyketides by using a type III polyketide synthase (PKS) and tailoring enzymes originating from a type II PKS system. The current study showcases the power of using transient expression in Nicotiana benthamiana for efficient and rapid identification of functional biosynthetic pathways, including both soluble and membrane-bound enzymes.

Forskolin is a unique structurally complex labdane-type diterpenoid used in the treatment of glaucoma and heart failure based on its activity as a cyclic AMP booster. Commercial production of forskolin relies exclusively on extraction from its only known natural source, the plant Coleus forskohlii, in which forskolin accumulates in the root cork. Here, we report the discovery of five cytochrome P450s and two acetyltransferases which catalyze a cascade of reactions converting the forskolin precursor 13R-manoyl oxide into forskolin and a diverse array of additional labdane-type diterpenoids. A minimal set of three P450s in combination with a single acetyl transferase was identified that catalyzes the conversion of 13R-manoyl oxide into forskolin as demonstrated by transient expression in Nicotiana benthamiana. The entire pathway for forskolin production from glucose encompassing expression of nine genes was stably integrated into Saccharomyces cerevisiae and afforded forskolin titers of 40 mg/L. DOI: http://dx.doi.org/10.7554/eLife.23001.001, eLife digest Unlike animals, plants cannot move away from a herbivore or other threats. Instead, they have evolved to produce a vast array of chemical compounds to protect themselves. Some of these compounds are also important to humans, for example, as medicines or fragrances. Plants usually only produce small amounts of these compounds in mixtures with many other compounds, which makes it difficult to purify them. As a result, the methods of purifying the compounds may require huge amounts of plant material, or be expensive and not environmentally friendly. One solution to this would be to genetically engineer microbes like bacteria or yeast to produce the compounds instead. In order to do that, we need to understand exactly which enzymes the plant uses to make each compound and introduce them into suitable microbes. A compound called forskolin has been used since ancient times in traditional Indian medicine to treat conditions like high blood pressure, asthma and heart complications. Forskolin is found exclusively in the root of a plant called Coleus forskohlii, which is native to India and south-east Asia. It is stored inside cells within the bark of the root in structures called oil bodies, which are similar to oil drops. However, it is not known where forskolin is made, or which enzymes are involved. Pateraki, Andersen-Ranberg et al. set out to uncover how C. forskohlii produces this compound. The experiments show that forskolin is produced within the cells that contain the oil bodies. A technique called RNA sequencing was used to identify several genes that are highly active in these cells and encode enzymes that could potentially be involved in producing forskolin. Further experiments demonstrated that these enzymes drive a cascade of chemical reactions that convert a molecule called 13R-manoyl oxide into forskolin. Next, Pateraki, Andersen-Ranberg et al. inserted the genes into yeast cells that could already produce 13R-manoyl oxide, which allowed the yeast to produce relatively high amounts of forskolin. These findings show that it is possible to identify the genes involved in the production of medicinal compounds in a relatively short amount of time. This knowledge will aid the development of a method that can be used to produce forskolin and other similar compounds on a large scale without needing to harvest C. forskohlii plants. DOI: http://dx.doi.org/10.7554/eLife.23001.002

Forskolin, a complex labdane diterpenoid found in the root of Coleus forskohlii (Lamiaceae), has received attention for its broad range of pharmacological activities, yet the biosynthesis has not been elucidated. We detected forskolin in the root cork of C. forskohlii in a specialized cell type containing characteristic structures with histochemical properties consistent with oil bodies. Organelle purification and chemical analysis confirmed the localization of forskolin and of its simplest diterpene precursor backbone, (13R) manoyl oxide, to the oil bodies. The labdane diterpene backbone is typically synthesized by two successive reactions catalyzed by two distinct classes of diterpene synthases. We have recently described the identification of a small gene family of diterpene synthase candidates (CfTPSs) in C. forskohlii. Here, we report the functional characterization of four CfTPSs using in vitro and in planta assays. CfTPS2, which synthesizes the intermediate copal-8-ol diphosphate, in combination with CfTPS3 resulted in the stereospecific formation of (13R) manoyl oxide, while the combination of CfTPS1 and CfTPS3 or CfTPS4 led to formation of miltiradiene, precursor of abietane diterpenoids in C. forskohlii. Expression profiling and phylogenetic analysis of the CfTPS family further support the functional diversification and distinct roles of the individual diterpene synthases and the involvement of CfTPS1 to CfTPS4 in specialized metabolism and of CfTPS14 and CfTPS15 in general metabolism. Our findings pave the way toward the discovery of the remaining components of the pathway to forskolin, likely localized in this specialized cell type, and support a role of oil bodies as storage organelles for lipophilic bioactive metabolites.

The seed oil of Euphorbia lathyris L. contains a series of macrocyclic diterpenoids known as Euphorbia factors. They are the current industrial source of ingenol mebutate, which is approved for the treatment of actinic keratosis, a precancerous skin condition. Here, we report an alcohol dehydrogenase-mediated cyclization step in the biosynthetic pathway of Euphorbia factors, illustrating the origin of the intramolecular carbon-carbon bonds present in lathyrane and ingenane diterpenoids. This unconventional cyclization describes the ring closure of the macrocyclic diterpene casbene. Through transcriptomic analysis of E. lathyris L. mature seeds and in planta functional characterization, we identified three enzymes involved in the cyclization route from casbene to jolkinol C, a lathyrane diterpene. These enzymes include two cytochromes P450 from the CYP71 clan and an alcohol dehydrogenase (ADH). CYP71D445 and CYP726A27 catalyze regio-specific 9-oxidation and 5-oxidation of casbene, respectively. When coupled with these P450-catalyzed monooxygenations, E. lathyris ADH1 catalyzes dehydrogenation of the hydroxyl groups, leading to the subsequent rearrangement and cyclization. The discovery of this nonconventional cyclization may provide the key link to complete elucidation of the biosynthetic pathways of ingenol mebutate and other bioactive macrocyclic diterpenoids.

Plant derived diterpenoids are relevant as pharmaceuticals, food additives and fragrances, yet a broader industrial utilization of these bioproducts is limited due to their low natural abundance and high structural complexity. Mimicking the modularity of diterpene biosynthesis in plants, we constructed 51 functional diterpene synthase combinations, 41 of which were “new-to-nature”. Here, we demonstrate stereoselective biosynthesis in Nicotiana benthamiana of 47 diterpene skeletons including natural variants and novel enantiomeric or diastereomeric counterparts. Scalable biotechnological production for four selected industrially relevant targets was realized in engineered strains of Saccharomyces cerevisiae